SIGA Technologies, Inc. On Tuesday January 19, 2010, 12:30 pm
NEW YORK, Jan. 19, 2010 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA - News), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that it was contacted to arrange an emergency mock acquisition of its lead drug candidate and smallpox antiviral, ST-246® (Tecovirimat), by leading Israeli government health and defense officials. The mock acquisition was part of a simulated bioterror-related smallpox outbreak.
Dubbed Orange Flame 4, the simulation was the largest biodefense drill in Israeli history, and it capped a four-day conference recognized by the World Health Organization and co-sponsored the Home Front Command of the Israeli Defense Forces.
“While no drug was actually delivered in this exercise, Israeli authorities told us they had arranged for immediate transportation of as many courses as we could provide, fully understanding that our drug candidate is under advanced development with BARDA and not registered with FDA,” said Eric A. Rose, MD, SIGA’s Chief Executive Officer.
Dr. Rose was among the hundreds of experts from over 70 countries that observed the two-day exercise that took place in and around Tel Aviv, Israel.
As part of the scenario, two European nationals, who were supposedly infected with smallpox, posed as tourists and “exposed” the public at a number of high-traffic locations, including a hotel and sports stadium. The simulation involved more than 20,000 smallpox-exposed individuals who required immediate isolation and treatment, as well as initiation of a nationwide vaccination campaign.
“Israel is committed to, and an internationally recognized thought leader in, safety and preparedness. This exercise was an excellent opportunity to observe a full simulation of a biological attack. It highlighted that a bioterror attack is a highly plausible scenario, which poses a significant threat to all civilized society. Observers of this exercise understood that the two critical elements in minimizing the after-effects of a bioterror attack are efficient planning and safe and effective medical countermeasures,” concluded Dr. Rose.
ST-246 has been used in three compassionate use cases in the United States and will be undergoing final safety and toxicity trials as part of the U.S. regulatory approval process. The company also has bid for a contract under an outstanding request for proposal by BARDA to supply the Strategic National Stockpile with a smallpox antiviral.
About SIGA Technologies, Inc.
SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's web site at http://www.siga.com/.
The SIGA Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4504
***** Do your research on this Company. They are going to get a contract from the US and it will open up the foreign buying.. Do your research!!!
Recent SIGA News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:58:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:06:24 PM
- SIGA Reports Financial Results for Three Months Ended March 31, 2024 • GlobeNewswire Inc. • 05/07/2024 08:05:00 PM
- SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/01/2024 09:00:00 PM
- SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX® • GlobeNewswire Inc. • 04/01/2024 08:05:00 PM
- SIGA Names Larry Miller General Counsel • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023 • GlobeNewswire Inc. • 03/12/2024 08:05:00 PM
- SIGA Declares Special Cash Dividend of $0.60 Per Share • GlobeNewswire Inc. • 03/12/2024 11:30:00 AM
- SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/05/2024 12:30:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/01/2024 08:54:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:04:04 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:01:28 PM
- SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 01:49:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 10:00:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:05:39 PM
- SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023 • GlobeNewswire Inc. • 11/07/2023 09:05:00 PM
- SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 10/26/2023 11:30:00 AM
- SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries • GlobeNewswire Inc. • 10/23/2023 12:00:00 PM
- SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer • GlobeNewswire Inc. • 09/06/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 10:05:19 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 08:50:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 08:05:20 PM
- SIGA Reports Financial Results for Three and Six Months Ended June 30, 2023 • GlobeNewswire Inc. • 08/08/2023 08:05:00 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM